Thank you Madrigal for your support on this Medication Review Video Module.

In this clinical overview, Dr. Kimberly Brown, Associate Medical Director for Liver Transplantation at Henry Ford Hospital, provides a comprehensive update on Resmetirom — the first FDA-approved therapy for adults with MASH (Metabolic Dysfunction-Associated Steatohepatitis) and moderate to advanced fibrosis (F2–F3). Dr. Brown reviews the approved indication for Resmetirom, explains which patients are eligible for treatment, and offers practical guidance on dosing based on body weight and drug interactions. She also addresses common questions regarding use in patients with thyroid conditions and those already on GLP-1 therapies. With a favorable safety profile and minimal side effects—mainly mild nausea and diarrhea—Resmetirom represents a significant breakthrough in managing progressive liver disease. Learn more about proper dosing strategies, drug interactions (including statin use), and how to identify appropriate patients who may benefit from this liver-targeted therapy.